Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Life Sciences and Promosome Sign Licensing Agreement

Published: Tuesday, April 29, 2014
Last Updated: Tuesday, April 29, 2014
Bookmark and Share
Innovative mammalian cell line development technologies that show promise for increasing manufacturing efficiency of vital biopharmaceuticals.

GE Healthcare Life Sciences and Promosome LLC have announced that the companies have signed a licensing agreement, granting GE Healthcare exclusive rights to an innovative suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture.

Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.

Mammalian cell culture plays a key role in the manufacture of biotherapeutic proteins for the treatment of diseases such as cancer and rheumatoid arthritis, as well as the new generation of vaccines. GE Healthcare already offers a wide range of start-to-finish technologies and services for the biopharmaceutical manufacturing industry.

In-licensing of Promosome’s cell line development technologies will enable GE Healthcare Life Sciences to expand its offering with a cell-line generation service focused on delivering increased expression levels for hard-to-manufacture therapeutic proteins and improving manufacturing efficiency through increased protein yields.

Morgan Norris, General Manager for Upstream Products, BioProcess, GE Healthcare Life Sciences, said: “The biopharmaceutical industry is constantly looking for ways to improve efficiency and increase flexibility. Promosome’s technologies provide a powerful way to drive up protein yields and, more excitingly, boost the output of cell lines for hard-to-express proteins to a level where large-scale manufacturing becomes viable and previously disregarded therapies can be progressed.”

John Manzello, President and CEO of Promosome, added: “This agreement represents a significant commercial milestone for Promosome. We are excited to be working closely with the team at GE Healthcare to transfer our technology to their in-house experts. GE Healthcare is ideally positioned to deliver our technology to the global biopharmaceutical industry.”

GE Healthcare has recently acquired Thermo Fisher’s HyClone™ cell culture media and sera allowing GE to expand its offering of start-to-finish technologies for the discovery and manufacturing of innovative new medicines and vaccines. In 2012 the company launched KUBio™, an off-the-shelf modular factory for the manufacture of monoclonal antibodies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Expands European Capabilities
Expansion will see large volume sterile liquid handling capacity doubled.
Tuesday, April 12, 2016
GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
GE Healthcare’s 2012 Cell Imaging Competition - Voting Opens to Celebrate Art, Science and Discovery
Competition features both high-content analysis and high- and super-resolution microscopy cell images for the first time.
Thursday, November 22, 2012
Scientific News
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Puttng Cells Through Their Paces
An obstacle course for human lung cells could be the answer for better testing the effectiveness of potential new drugs.
Inherited Heart Condition Breakthrough
Using stem cells, scientists have created a specific heart condition model, yeilding insights into unexpected disease mechanisms.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
Origin of Cultured Cells: Not Where You Think
Study shows cultured cells from decades-old cell line does not originate from the patient it was claimed to derive from.
Hope for Zika Treatment Found in Drug Screening
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection.
Worms Point Way Toward Viral Strategies
Rice University wins NIH grant to study how nematodes handle gastrointestinal viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!